NDC 59310-610

CINQAIR

Reslizumab

CINQAIR is a Intravenous Injection, Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Teva Respiratory, Llc. The primary component is Reslizumab.

• Product ID: 59310-610_513ffaf8-bf9c-4f84-8ff6-4ac496d183d8
• NDC: 59310-610
• Product Type: Human Prescription Drug
• Proprietary Name: CINQAIR
• Generic Name: Reslizumab
• Dosage Form: Injection, Solution, Concentrate
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2016-04-18
• Marketing Category: BLA / BLA
• Application Number: BLA761033
• Labeler Name: Teva Respiratory, LLC
• Substance Name: RESLIZUMAB
• Active Ingredient Strength: 10 mg/mL
• Pharm Classes: Interleukin-5 Antagonist [EPC],Interleukin-5 Antagonists [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 59310-610-31

1 VIAL, SINGLE-USE in 1 CARTON (59310-610-31) > 10 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2016-04-18
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 59310-610-33 [59310061033]

CINQAIR INJECTION, SOLUTION, CONCENTRATE

• Marketing Category: BLA
• Application Number: BLA761033
• Product Type: HUMAN PRESCRIPTION DRUG
• Marketing Start Date: 2017-06-04

NDC 59310-610-31 [59310061031]

CINQAIR INJECTION, SOLUTION, CONCENTRATE

• Marketing Category: BLA
• Application Number: BLA761033
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2016-04-18

Drug Details

Active Ingredients

Ingredient	Strength
RESLIZUMAB	10 mg/mL

OpenFDA Data

• SPL SET ID: 053b9158-2a5b-48b9-bf47-5fa78a35ec33
• Manufacturer:
  • Teva Respiratory, LLC
• UNII:
  • 35A26E427H
• RxNorm Concept Unique ID - RxCUI:
  • 1746893
  • 1746898

Pharmacological Class

• Interleukin-5 Antagonist [EPC]
• Interleukin-5 Antagonists [MoA]